SCHEMBL29760002

SCHEMBL29760002

Cc1ncc(NC(=O)CN2CCC[C@H]2C)cc1NC(=O)c1cnn2cc(-c3cn(C)nc3C)sc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WNT1 P04628 3/20 0.39
▸ GSK3B P49841 3/20 0.39
▸ DYRK1A Q13627 3/20 0.39
▸ SSTR2 P30874 1/20 0.35
▸ HRH3 Q9Y5N1 6/20 0.35
▸ KMT2A Q03164 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ RAD52 P43351 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ PIM1 P11309 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ PDGFRA P16234 1/20 0.34
▸ HPGD P15428 2/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ RAF1 P04049 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29759579 1.00 WNT1 (0.39) WNT1GSK3BDYRK1ASSTR2HRH3
SCHEMBL29759484 0.90 GSK3B (0.47) WNT1GSK3BDYRK1AHRH3KMT2A
SCHEMBL29759460 0.90 GSK3B (0.47) WNT1GSK3BDYRK1AHRH3KMT2A
SCHEMBL29759997 0.89 WNT1 (0.38) WNT1GSK3BDYRK1AHRH3KMT2A
SCHEMBL29759670 0.87 SSTR2 (0.35) WNT1GSK3BDYRK1ASSTR2HRH3
SCHEMBL27185062 0.87 POLQ (0.36) WNT1GSK3BDYRK1AHRH3KMT2A
SCHEMBL29759989 0.87 POLQ (0.36) WNT1GSK3BDYRK1AHRH3KMT2A
SCHEMBL27185067 0.87 POLQ (0.36) WNT1GSK3BDYRK1AHRH3KMT2A
SCHEMBL29759721 0.86 GSK3B (0.40) WNT1GSK3BDYRK1AHRH3KMT2A
SCHEMBL30566501 0.86 GSK3B (0.40) WNT1GSK3BDYRK1AHRH3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 — — US disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 WNT1 2716/4885GSK3B 1914/4885DYRK1A 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback